Saturday 17 October 2026
Export TYRA’s income statement to Excel — free account
Tyra Biosciences, Inc.
TYRA Healthcare Biotechnology
In the quarter to June 2026, EPS fell 46.8% and free cash flow fell 31.3%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
18.52
0.52
−2.73%
Follow TYRA
Tyra Biosciences, Inc. (TYRA) P/E ratio
Tyra Biosciences, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 0.0× (October 2026) — the current reading is the highest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|
Against its own ten years
Low 0.0×
High 0.0×
Ten-year median
0.0×
Current reading's percentile
100
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| GHRS GH Research PLC compare | n/m |
| TYRA Tyra Biosciences, Inc. | n/m |
| NKTR Nektar Therapeutics compare | n/m |
| DRTS Alpha Tau Medical Ltd. compare | n/m |
| ORIC Oric Pharmaceuticals, Inc. compare | n/m |
| INBX Inhibrx Biosciences, Inc. compare | n/m |
| SNDX Syndax Pharmaceuticals, Inc. compare | n/m |
| OMER Omeros Corporation compare | 9.5× |
| AAPG Ascentage Pharma Group International - Unsponsored ADR compare | — |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)